Anti-viral compositions
AssigneeSyntex (U.S.A.) Inc.
InventorKendall O. Smith
Life of this patent
Estimating the term…
Abstract
Combinations of 9-[[2-hydroxy-1-(hydroxymethyl)-ethoxy]methyl]guanine and at least one other antivirally active drug such as phosphonoacetic acid and its salts, phosphonoformic acid and its salts, acycloguanosine, or a 5-(2-halogenovinyl)-2'-deoxyuridine show synergy in their activity against various herpes virus infections including HSV-1 and HSV-2.
Claims11
A therapeutic composition having activity against herpes viral infections and comprising, in combiantion:
- 9-[[2-hydroxy-1-(hydroxymethyl)-ethoxy]methyl[guanine, as a first active component, and
- a second active component selected from the group consisting of phosphonoacetic acid and pharmaceutically acceptable salts thereof, phosphonoformic acid and pharmaceutically acceptable salts thereof, acycloguanosine, and a 5-(2-halogenovinyl)2'-deoxyuridine;
- said first and second active components being present in anti-virally active relative synergistic amounts from a ratio of about 1:200 to about 1:1 on a molar basis.
A therapuetic composition having activity against herpes viral infections and comprising, in combination, 9-[[2-hydroxy-1-(hydroxymethyl)-ethoxy]methyl-guanine, as a first active component, and bromovinyl-deoxyuridine as a second active component, said first and second active components being present in anti-virally active relative synetgistic amounts from a ratio of about 1:200 to about 25:1 on a molar basis.
A therapeutic composition having activity against herpes viral infections and comprising, in combination:
- 9-[[2-hydroxy-1-(hydroxymethyl)-ethoxy]methyl]guanine, as a first active component, and
- a second active component selected from the groups consisting of:
- phosphonoacetic acid and pharmaceutically acceptable salts thereof, present in an amount, with respect to said first active component, from a ratio of about 1:378 to about 1:1 on a molar basis;
- and
- phosphonoformic acid and pharmaceutically acceptable salts thereof, present in an amount, with respect to said first active component, from a ratio of about 1:234 to about 1:1 on a molar basis.
Dependencies are inferred from the claim text.